Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,825 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Surgery for early-stage small cell lung cancer.
Schneider BJ, Saxena A, Downey RJ. Schneider BJ, et al. Among authors: saxena a. J Natl Compr Canc Netw. 2011 Oct;9(10):1132-9. doi: 10.6004/jnccn.2011.0094. J Natl Compr Canc Netw. 2011. PMID: 21975913 Review.
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, Gruden JF, Christos PJ, Spinelli C, Gakuria J, Uppal M, Binder B, Elemento O, Ballman KV, Formenti SC. Altorki NK, et al. Among authors: saxena a. Lancet Oncol. 2021 Jun;22(6):824-835. doi: 10.1016/S1470-2045(21)00149-2. Epub 2021 May 18. Lancet Oncol. 2021. PMID: 34015311 Clinical Trial.
Advancements in small cell lung cancer.
Lee JH, Saxena A, Giaccone G. Lee JH, et al. Among authors: saxena a. Semin Cancer Biol. 2023 Aug;93:123-128. doi: 10.1016/j.semcancer.2023.05.008. Epub 2023 May 24. Semin Cancer Biol. 2023. PMID: 37236329 Review.
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin AD, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE. Altorki NK, et al. Among authors: saxena a. Nat Commun. 2023 Dec 19;14(1):8435. doi: 10.1038/s41467-023-44195-x. Nat Commun. 2023. PMID: 38114518 Free PMC article.
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin AD, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE. Altorki NK, et al. Among authors: saxena a. Nat Commun. 2024 Jan 3;15(1):225. doi: 10.1038/s41467-023-44575-3. Nat Commun. 2024. PMID: 38172131 Free PMC article. No abstract available.
3,825 results